Vancouver BC, March 24, 2020  Precision Nanosystems, Inc. (PNI), a global leader in enabling transformative nanomedicines announced today that the company entered into a license agreement with FUJIFILM Corporation to adopt PNI’s NanoAssemblr™ technology and complete suite of instruments for Fujifilm’s state-of-the-art manufacturing facility, compatible with GMP regulations of US, Europe and Japan.

As part of this agreement, Fujifilm has the rights to offer contract manufacturing services using PNI’s proprietary technology and also use PNI technology to develop and commercialize its internal therapeutic drug products. PNI and Fujifilm will work together to combine and democratize the scalable manufacturing of gene therapy and small-molecule based nanomedicines using Fujifilm’s and PNI’s proprietary technologies.

PNI’s NanoAssemblr technology is powered by the disruptive NxGen microfluidics mixing technology designed exclusively for scalable nanomedicine development while maintaining precise control and reproducibility. The NanoAssemblr platform is comprised of the Spark, Ignite, Blaze and GMP Systems that together offer a flexible solution for accelerated, cost-effective development and scalable manufacture of high-quality gene therapy, small molecule and protein-based nanomedicine products.

James Taylor, Co-Founder and CEO of PNI said, “We are thrilled to work with Fujifilm to enable our technology in support of clinical clients as they progress their therapeutic programs from the laboratory to the clinic and commercial. Fujifilm’s R&D teams will combine the PNI platform and their proprietary Drug Delivery Systems technologies and we look forward to the seamless scaling up and manufacturing of innovative medicines to impact human well-being.”

Nanomedicines is one of the focus areas of Fujifilm, tapping into its advanced technologies such as nano-technology, process engineering technology and analysis technology. “We are excited to work with PNI to bring on board the NanoAssemblr suite of products and cutting-edge nanomedicines manufacturing technology,” said Junji Okada, Senior Vice President, General Manager of Pharmaceutical products division, FUJIFILM Corporation. “Tapping into Fujifilm’s state of the art technology, expertise and the facility for the provision of pre-clinical and GMP manufacturing services, we are committed to creating innovative and high-value pharmaceutical products not only through internal development but also by providing high quality liposomal formulations to our partner companies.”

About Precision NanoSystems Inc.

Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com.

About Fujifilm Corporation

FUJIFILM Corporation, Tokyo, Japan is one of the major operating companies of FUJIFILM Holdings Corporation. The company brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2019, the company had global revenues of $22 billion, at an exchange rate of 111 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.